Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Oral Solution

Known as: OralSolution, Oral Solution [Dose Form], Oral Sol 
A solution intended for oral administration.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective 
Highly Cited
2009
Highly Cited
2009
  • figure 1
  • figure 2
  • figure 4
Highly Cited
2004
Highly Cited
2004
PURPOSE Oral mucositis (OM) causes significant morbidity during the course of radiotherapy (RT) treatment of head-and-neck cancer… 
Review
2001
Review
2001
UNLABELLED Cyclosporin is a lipophilic cyclic polypeptide immunosuppressant that interferes with the activity of T cells chiefly… 
  • figure 1
  • table I
  • table II
  • figure 2
  • table III
Review
2001
Review
2001
Itraconazole is a triazole antifungal agent with a broad spectrum of activity. It is well tolerated and highly efficacious… 
Review
2001
Review
2001
Prolonged neutropenia is a major risk factor for invasive fungal infection (1-6). The incidence among neutropenic patients with… 
Highly Cited
1999
Highly Cited
1999
To evaluate the efficacy and safety of itraconazole oral solution for preventing fungal infections, a randomized, placebo… 
Highly Cited
1991
Highly Cited
1991
Oral transmucosal fentanyl citrate (OTFC) is a novel, noninvasive dosage form of fentanyl used to provide children and adults… 
Review
1989
Review
1989
Midodrine, a peripheral alpha-adrenergic agonist, finds use in the clinical management of patients with orthostatic hypotension… 
  • figure 1
  • figure 2
  • table I
  • table II
  • table IV
Review
1986
Review
1986
Omeprazole is a substituted benzimidazole derivative which markedly inhibits basal and stimulated gastric acid secretion. It has… 
  • figure 1
  • figure 2
  • table I
  • figure 3
  • figure 4